original ) (raw )Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue
Sergio Morelli
Heart (British Cardiac Society), 2001
View PDFchevron_right
Effects of Long-term Infusion of Prostacyclin on Exercise Performance in Patients With Primary Pulmonary Hypertension
Robert Garofano
Chest, 1999
View PDFchevron_right
Long-Term Treatment of Pulmonary Arterial Hypertension With Treprostinil: Echocardiographic Evaluation of Efficacy
Annarita Vestri
CHEST Journal, 2003
View PDFchevron_right
Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost
George Cremona
Heart (British Cardiac Society), 1998
View PDFchevron_right
Perfusion lung scan as a prognostic indicator of response to beraprost sodium in idiopathic pulmonary arterial hypertension
JU NA
Pulmonary Pharmacology & Therapeutics, 2006
View PDFchevron_right
Comparative effects of beraprost, a stable analogue of prostacyclin, with PGE1, nitroglycerin and nifedipine on canine model of vasoconstrictive pulmonary hypertension
Hajimu Kurumatani
Prostaglandins, Leukotrienes and Essential Fatty Acids, 2001
View PDFchevron_right
Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue
Michael Hamm
New England Journal of Medicine, 2000
View PDFchevron_right
Vasoactive therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease
Debasis Sahoo
Respiratory Medicine, 2008
View PDFchevron_right
Comparative Effectiveness and Safety of Drug Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
Brooke Heidenfelder , Rowena Dolor
CHEST Journal, 2013
View PDFchevron_right
Hemodynamic Efficacy of Beraprost Therapy in Systemic Sclerosis-Related Pulmonary Artery Hypertension
Ratanavadee Nanagara
View PDFchevron_right
Successful management of portopulmonary hypertension with beraprost
tae yong ahn
European Journal of Gastroenterology & Hepatology, 2010
View PDFchevron_right
Pulmonary Artery Pressure–Flow Relations after Prostacyclin in Primary Pulmonary Hypertension
philippe herve
American Journal of Respiratory and Critical Care Medicine, 2002
View PDFchevron_right
Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2
James Klinger
Circulation, 2008
View PDFchevron_right
New Insights in the Treatment Strategy for Pulmonary Arterial Hypertension
Ryozo Nagai
Cardiovascular Drugs and Therapy, 2006
View PDFchevron_right
Assessment of the vasodilator response in primary pulmonary hypertension Comparing prostacyclin and iloprost administered by either infusion or inhalation
Michael Linscheid
European Heart Journal, 2003
View PDFchevron_right
A review of pulmonary arterial hypertension: Part 2: Current and expected treatments
Pieter E Postmus
View PDFchevron_right
A Mixed Treatment Comparison Meta-Analysis of Pharmacotherapeutic Monotherapy and Placebo for Pulmonary Artery Hypertension
Milka Njoroge
Clinical Pulmonary Medicine, 2017
View PDFchevron_right
Management Of Pulmonary Arterial Hypertension: A Brief Overview
Shatavisa Mukherjee
2017
View PDFchevron_right
Actual and novel treatments for pulmonary hypertension
Thomas Unger
Hypertension News, 2021
View PDFchevron_right
Long-Term Pulmonary Hemodynamic Effects of Ambrisentan in Pulmonary Arterial Hypertension
James Klinger
The American Journal of Cardiology, 2011
View PDFchevron_right
Comparative effects of losartan and nifedipine therapy on exercise capacity, Doppler echocardiographic parameters and endothelin levels in patients with secondary pulmonary hypertension
Füsun Eyüboğlu
Anadolu Kardiyoloji Dergisi/The Anatolian Journal of Cardiology, 2010
View PDFchevron_right
Current Pharmacological Treatment of Pulmonary Arterial Hypertension
Paschalis Steiropoulos
Current Clinical Pharmacology, 2008
View PDFchevron_right
Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension
Werner Seeger
Journal of the American College of Cardiology, 2004
View PDFchevron_right
Oral Prostacyclin Therapy for Pulmonary Arterial Hypertension : Another Step Forward
Aaron Waxman
View PDFchevron_right
Prostacyclin and Iloprost in the Treatment of Primary Pulmonary Hypertension
Christopher McCabe
View PDFchevron_right
Survival with first-line bosentan in patients with primary pulmonary hypertension
O. Sitbon
European Respiratory Journal, 2005
View PDFchevron_right
Clinical Trials Using Vasodilators in Pulmonary Arterial Hypertension:Where Do We Go from Here?
Javier Mariani
Reviews on Recent Clinical Trials, 2011
View PDFchevron_right
Recent Trends in the Management of Pulmonary Hypertension
Mukhyaprana Prabhu
2005
View PDFchevron_right
The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: Demonstration of a ceiling effect
Nicholas Hill , Evelyn Horn
Vascular Pharmacology, 2005
View PDFchevron_right
Key Articles and Guidelines in the Management of Pulmonary Arterial Hypertension: 2011 Update
Tyree Kiser
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
View PDFchevron_right
Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension
Caterina Marciano
European Respiratory Journal, 2012
View PDFchevron_right
A review of pulmonary arterial hypertension: Part 1. Novel insights and classification
Pieter E Postmus
View PDFchevron_right
Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension
Lucie Clapp
Biochemical Pharmacology, 2019
View PDFchevron_right